MICONAZOLE 7 pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich	⤷ Start Trial	M3512_SIGMA	⤷ Start Trial
TCI (Tokyo Chemical Industry)	⤷ Start Trial	M1769	⤷ Start Trial
Molport	⤷ Start Trial	MolPort-003-665-537	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 6, 2025

Introduction

The pharmaceutical industry relies heavily on the supply chain of active pharmaceutical ingredients (APIs), with sourcing strategies playing a crucial role in ensuring quality, regulatory compliance, and cost-effectiveness. Miconazole, a broad-spectrum antifungal agent, is extensively utilized in topical, vaginal, and systemic formulations. The 7% concentration, often used in dermatological preparations, demands a consistent, high-quality API supply to meet global demand effectively.

This analysis explores the primary sources for bulk Miconazole 7% API, including manufacturing hubs, key players, sourcing considerations, and regulatory aspects, supporting pharmaceutical companies in strategic procurement and risk mitigation.

Global Manufacturing Landscape for Miconazole API

1. Leading Producing Countries

The global API manufacturing network for Miconazole predominantly encompasses regions with established pharmaceutical manufacturing capacities, notably:

India: Dominant in generic API production, India boasts numerous WHO-GMP-certified facilities, offering cost-effective and high-volume APIs. Indian manufacturers like Sun Pharma, Cipla, and Ajanta Pharma are notable for their API capacities, including Miconazole (Source: Indian Pharmacopoeia, 2022).
China: A significant API manufacturing hub characterized by rapid growth, technological advancements, and large-scale production. Chinese firms such as Zhejiang Hengan Pharmaceutical and Zhejiang Hanzhong Pharmaceutical produce Miconazole API, complying with international standards (Source: China National Pharmaceutical Inspection Cooperation).
European Union and North America: Tertiary suppliers primarily cater to niche or high-specification markets, often sourcing APIs from Indian or Chinese manufacturers with strict GMP compliance to meet regulatory requirements (Source: European Medicines Agency).

2. Leading API Manufacturers for Miconazole 7%

Several manufacturers worldwide are recognized for producing bulk Miconazole API explicitly or as part of broader antifungal APIs:

Zhejiang Hanzhong Pharmaceutical (China): Known for bulk miconazole production with certifications aligned with international standards, supplying large volumes to global clients.
Macleods Pharmaceuticals (India): While primarily a finished dosage form manufacturer, it maintains API supply capabilities, including miconazole, from India-based facilities.
Akyta Pharmaceuticals (India): Offers high-quality Miconazole API, adhering to cGMP regulations, with contracts supporting the topical antifungal market.
SNPharm (India): Specialized in antifungal APIs, including Miconazole, with extensive differentials in supply chains.
Taj Pharmaceuticals (India): Provides bulk API manufacturing services and exports globally, compliant with certifications such as US FDA and EDQM standards.

Note: Manufacturers’ certifications and compliance with regulatory standards such as API-specific WHO-GMP, US FDA, EDQM, and EMA are key considerations when sourcing [1].

Sourcing Considerations for Miconazole API

1. Quality and Regulatory Compliance

Ensuring API quality involves validation of:

GMP Certification: Preferential sourcing from certified facilities complying with WHO-GMP, US FDA, EMA, or PIC/S standards.
Analytical Data & Certificates of Analysis (CoA): Critical for verifying potency, purity, and stability aligned with pharmacopoeia standards (e.g., USP, BP, EP, JP).
Batch-to-batch consistency: Essential for maintaining product efficacy, especially in topical formulations where API integrity impacts safety.

2. Cost Optimization and Supply Chain Reliability

Pricing Dynamics: Indian and Chinese suppliers typically offer competitive pricing due to lower manufacturing costs but must be evaluated for quality assurance.
Lead Times & Capacity: Larger manufacturers with extensive capacity mitigate supply disruption risks, ensuring continuous production.

3. Regulatory and Legal Factors

Import Regulations: Several countries impose tariffs, quotas, or licensing requirements—due diligence on import documentation and registration is advisable.
Intellectual Property & Patent Considerations: As Miconazole is off-patent, generic sources are widespread, simplifying procurement.

4. Environmental & Ethical Standards

Environmental Regulations: Ensure suppliers meet environmental compliance standards, reducing risks associated with regulatory sanctions.
Corporate Social Responsibility (CSR): Ethical sourcing emphasizes workers’ safety, fair wages, and sustainable practices.

Regulatory Considerations

Sourcing APIs like Miconazole involves navigating complex regulatory landscapes:

Pharmacopoeial Compliance: Manufacturers must ensure APIs conform with pharmacopoeia standards (USP, EP, BP).
Global Regulatory Agencies: For market approval, APIs must be sourced from suppliers compliant with agencies like the US FDA, EMA, or WHO.
GMP Certification Validity: Continuous verification of certifications is crucial for maintaining regulatory approvals.
Import & Export Licenses: Establishment of documentation aligned with cGMP and customs requirements streamlines cross-border transactions.

Emerging Trends and Strategic Sourcing

1. Contract Manufacturing & Sourcing Alliances

Pharmaceutical firms increasingly adopt strategic alliances with global API manufacturers to secure supply chains, leverage technological advancements, and reduce costs. Contract manufacturing organizations (CMOs) with proven quality records become preferred partners.

2. Dual Sourcing Strategies

Diversifying API suppliers across regions minimizes risk due to geopolitical tensions, supply chain disruptions, or regulatory hurdles.

3. Focus on Sustainability and Green Manufacturing

Increasing demand for environmentally responsible APIs prompts investment in greener manufacturing processes, which may affect sourcing choices long-term.

Conclusion

The global landscape for Miconazole 7% API sourcing is characterized by a robust manufacturing presence in India and China, with a tier of quality-focused suppliers across various regions. Ensuring a reliable supply chain necessitates diligent supplier qualification, compliance verification, and strategic diversification. Staying ahead requires continuous monitoring of regulatory updates, technology advancements, and sustainable practices.

Key Takeaways

Indian and Chinese manufacturers dominate Miconazole API production, offering high-quality, cost-effective options.
Quality assurance through GMP certification and detailed analytical data is non-negotiable.
Diversified sourcing and partnerships with reputable CMOs can mitigate supply risks.
Regulatory compliance and environmental standards influence supplier selection.
Ongoing industry trends favor green manufacturing and strategic alliances for resilient supply chains.

FAQs

1. What are the leading countries producing Miconazole API?
India and China are the primary producers, with manufacturers such as Zhejiang Hanzhong Pharmaceutical and several Indian firms leading production capacity.

2. How do I ensure API quality from overseas suppliers?
Verify GMP certification, review Certificates of Analysis, and conduct audits or third-party inspections to confirm compliance with pharmacopoeial standards.

3. Are there regulatory concerns when sourcing Miconazole API globally?
Yes. Ensure suppliers meet local and international regulatory requirements, including FDA, EMA, or WHO-GMP certifications, to facilitate smooth importation and registration.

4. What factors influence the cost of Miconazole API?
Production costs, supplier capacity, quality standards, and geopolitical factors impact pricing; Indian manufacturers often offer competitive rates.

5. Is dual sourcing recommended for Miconazole API?
Yes, to mitigate risks associated with supply disruptions, diversification across multiple qualified suppliers is advisable.

References

Indian Pharmacopoeia Commission. (2022). Indian Pharmacopoeia. Ministry of Health & Family Welfare.
China National Pharmaceutical Inspection Cooperation. (2022). API Manufacturing Standards.
European Medicines Agency. (2023). Guidelines on Good Manufacturing Practice.
US Food and Drug Administration. (2023). API Quality Standards.

Bulk Pharmaceutical API Sources for MICONAZOLE 7